Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints Rob Gallo as head of corporate communications, Europe and Canada

Will lead efforts to combine communications efforts in two regions

Rob Gallo - TakedaJapan-based Takeda Pharmaceuticals has promoted its interim head of corporate communications for Europe Rob Gallo to a permanent role that also covers Canada.

Gallo had been in his interim position since 2010, overseeing Europe-wide media campaigns, and will now be based at Takeda's regional headquarters in Zurich, Switzerland.

His new responsibilities will include unifying local communication teams as Takeda prepares to combine its Canadian and European businesses into a single Takeda subsidiary, ensuring communication aligns to the company's new strategic model as well as preparing teams for the launch of several products.

Gallo said: “I am delighted to be joining Takeda permanently to help deliver corporate objectives in what is a very exciting stage of the company's development.”

Before joining Takeda, Gallo was a director of Operandi Partners, a corporate communications and issues management consultancy based in London. 

In addition to his pharmaceutical experience, he has also held senior communications posts across a range of FMCG companies in the UK, Italy and Australia.

13th July 2012

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....